Department of Epidemiology, and.
ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York.
Clin Infect Dis. 2017 May 15;64(10):1309-1316. doi: 10.1093/cid/cix162.
As access to antiretroviral therapy (ART) in Africa has increased dramatically, concerns have been raised regarding patient attrition, an important measure of program quality.
We examined aggregate data from 307144 patients initiating ART in 5638 successive cohorts at 638 facilities in 9 African countries from 2005 to 2010, a period characterized by massive treatment expansion. Poisson regression assessed trends in 6- and 12-month cohort attrition (ie, the proportion of patients in each cohort no longer receiving ART at their initiating facility) over calendar time and as ART services matured, and identified factors associated with attrition.
Across all 9 countries, 6- and 12-month cohort attrition was 21% and 29%, respectively, with no decrease over calendar time (6-month P = .8735; 12-month P = .5717) or as ART services matured (6-month P = .3005; 12-month P = .2277). Additionally, attrition remained stable or decreased across both measures in nearly all countries. Initiating ART in facilities with more documented transfers and fewer women on ART, and in cohorts with poor CD4 count documentation and lower median CD4 count at ART initiation was associated with increased 6-month attrition. Increased 12-month attrition was observed in semiurban facilities and those with more documented transfers, and in cohorts with poor CD4 count documentation, whereas higher patient load was associated with decreased attrition.
Stable or decreasing trends in attrition for ART patients were observed in most countries, suggesting programs can be expanded without compromising quality. However, further reductions in attrition are needed to maximize individual and population benefits of ART.
随着非洲获得抗逆转录病毒疗法(ART)的机会大大增加,人们对患者流失率(衡量项目质量的一个重要指标)表示担忧。
我们分析了 2005 年至 2010 年期间,9 个非洲国家的 638 个机构中 5638 个连续队列的 307144 名开始接受 ART 的患者的汇总数据,该时期的特点是大规模治疗扩展。泊松回归评估了在日历时间和随着 ART 服务成熟的情况下,6 个月和 12 个月队列流失率(即在每个队列中不再在初始机构接受 ART 的患者比例)的趋势,并确定了与流失率相关的因素。
在所有 9 个国家中,6 个月和 12 个月的队列流失率分别为 21%和 29%,随着日历时间的流逝没有下降(6 个月 P =.8735;12 个月 P =.5717)或随着 ART 服务的成熟(6 个月 P =.3005;12 个月 P =.2277)。此外,几乎所有国家的这两个指标的流失率都保持稳定或下降。在记录更多转介和更少接受 ART 的女性的机构中开始接受 ART,以及在 CD4 计数记录较差和开始接受 ART 时 CD4 计数中位数较低的队列中,6 个月的流失率增加。在半城市设施和记录更多转介的设施中以及在 CD4 计数记录较差的队列中,12 个月的流失率增加,而较高的患者负担与较低的流失率相关。
在大多数国家中,ART 患者的流失率呈稳定或下降趋势,这表明在不影响质量的情况下可以扩大项目。然而,需要进一步降低流失率,以最大限度地提高个人和人群接受 ART 的益处。